Bayesian Capital Management, LP Halozyme Therapeutics, Inc. Transaction History

Bayesian Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $1.18 Million - $1.64 Million	31,260 New	31,260 $1.64 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $1.05 Million - $1.33 Million	31,500 New	31,500 $1.16 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $260,408 - $333,164	8,600 Added 22.93%	46,100 $1.66 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $982,514 - $1.67 Million	29,900 Added 393.42%	37,500 $1.43 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $340,510 - $505,240	-8,500 Reduced 52.8%	7,600 $432,000
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $146,414 - $196,764	-3,800 Reduced 19.1%	16,100 $637,000
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $743,265 - $961,170	19,900 New	19,900 $876,000
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $300,066 - $362,076	-7,800 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$38.84 - $51.31 $25,828 - $34,121	-665 Reduced 7.86%	7,800 $354,000
Q1 2021 May 14, 2021	BUY	$39.51 - $51.45 $334,452 - $435,524	8,465 New	8,465 $353,000
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $388,967 - $483,360	-22,800 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$16.75 - $20.8 $381,900 - $474,240	22,800	22,800 $462,000

542

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.36B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.